Cover

Current and Future Management of Brain Metastasis

Editor(s): Kim D.G. (Seoul) 
Lunsford L.D. (Pittsburgh, Pa.) 
Table of Contents
Vol. 25, 2012
Section title: General Management
Kim DG, Lunsford LD (eds): Current and Future Management of Brain Metastasis. Prog Neurol Surg. Basel, Karger, 2012, vol 25, pp 55–73
(DOI:10.1159/000331174)

Imaging Diagnosis of Brain Metastasis

Barajas Jr. R.F. · Cha S.
Departments of aRadiology and Biomedical Imaging and bNeurological Surgery, University of California, San Francisco, Calif, USA

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Complete book

  • Immediate access to all parts of this book
  • Cover-to-cover formats may be available
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restriction for personal use
read more

Pricing depends on hard-cover price


Select


Article / Publication Details

First-Page Preview
Abstract of General Management

Published online: 1/6/2012
Cover Date: 2012

Number of Print Pages: 19
Number of Figures: 18
Number of Tables: 2

ISBN: 978-3-8055-9617-6 (Print)
eISBN: 978-3-8055-9618-3 (Online)

Abstract

Hematogeneous spread of primary neoplasm can result in central nervous system (CNS) disease burden in various anatomically distinct regions; calvarial, pachymeningeal, leptomeningeal, and intraparenchymal. The choice of imaging modality is dependent on the individual clinical situation, but, largely depends on the patients overall clinical status and the information needed to make treatment decisions. Contrast-enhanced magnetic resonance (MR) imaging is the preferred imaging modality of choice; however, computed tomography (CT) is often utilized as the first-pass screening modality for CNS disease. Despite the superior soft tissue resolution, multiplanar capability, and noninvasive nature of MR imaging, T1- and T2-weighted sequences are limited to delineating morphologic anatomical deraignment of tissues by tumor. Several physiology based MR imaging sequences have been developed which compliment anatomic MR imaging. Proton magnetic resonance spectroscopic and dynamic susceptibility contrast-enhanced perfusion-weighted imaging are two physiologic sequences which add additional diagnostic information allowing for improved tumor characterization. Common pitfalls in evaluating for metastatic disease burden include the misidentification of non-neoplastic hematomas, remote microvascular ischemia, and acute onset of ischemic stroke. In the pediatric population, CNS metastases are rare; however, the onset of acute neurological symptoms in a child with known primary tumor should prompt imaging of the neuroaxis.


  

Author Contacts

Soonmee Cha, MD, UCSF Department of Radiology and Biomedical Imaigng, 505 Parnassus Ave, Long L200B, Box 0628, San Francisco, CA 94143 (USA), Tel. +1 415 353 8919, E-Mail soonmee.cha@radiology.ucsf.edu

  

Article Information

Published online: January 06, 2012
Number of Print Pages : 19

  

Publication Details

Book Serie: Progress in Neurological Surgery, Vol. 25, Year 2012

Editor(s): Lunsford, L.D. (Pittsburgh, Pa
ISSN: 0079-6492 (Print), eISSN: 1662-3924 (Online)

For additional information:
http://content.karger.com/ProdukteDB/produkte.asp?issn=0079-6492

Book Title: Current and Future Management of Brain Metastasis

Editor(s): Kim DG, Lunsford LD (eds)

For additional information:
http://content.karger.com/ProdukteDB/produkte.asp?issn=0079-6492&volume=25


Article / Publication Details

First-Page Preview
Abstract of General Management

Published online: 1/6/2012
Cover Date: 2012

Number of Print Pages: 19
Number of Figures: 18
Number of Tables: 2

ISBN: 978-3-8055-9617-6 (Print)
eISBN: 978-3-8055-9618-3 (Online)


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.